China SXT Pharmaceuticals EBIT

China SXT Pharmaceuticals posts a EBIT of $-8.5M as of March 2026. That compares with $2M in the prior-year period — down 533.5% year over year. That is below the Consumer Discretionary sector average of $150B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China SXT Pharmaceuticals's EBIT was $2M. The latest reading is $-8.5M — a 533.5% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Consumer Discretionary stocks, a EBIT near $150B is typical. China SXT Pharmaceuticals's $-8.5M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of China SXT Pharmaceuticals's financial statement story. At $-8.5M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SXTC's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $150B), and (3) consistency with growth and profitability. This page covers the first two; China SXT Pharmaceuticals's other metric pages and overview cover the third.